Meta-analysis of 19 studies (n=864) of advanced therapies for IBD with primary sclerosing cholangitis: pooled clinical response 52%, clinical remission 43%, endoscopic remission 26%; infections occurred in 22% and acute cholangitis in 14%. Heterogeneity was high.
Meta-analysisn = 864
Li et al. Advanced therapies for inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and meta-analysis